Itraconazol Cinfa (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a member of the cytochrome P450 family. By inhibiting this enzyme, the drug prevents the synthesis of ergosterol, an essential component of the fungal cell membrane, leading to membrane destabilisation and inhibition of fungal growth.

The exact dosage of Itraconazol Cinfa is determined by the prescribing clinician based on the type and severity of the infection, patient weight, age, liver function, and other clinical factors. Healthcare professionals tailor the regimen to each individual case.

Safety data for itraconazole during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The most common alternative in the azole class is fluconazole. Itraconazole has a broader spectrum against dermatophytes, dimorphic fungi, and some molds, whereas fluconazole is more active against Candida species but less effective for onychomycosis and certain systemic infections. Choice depends on the pathogen and infection site.

Store Itraconazol Cinfa at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat, and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Itraconazol Cinfa is taken orally, usually with food or a full glass of water to improve absorption. The tablet or capsule should be swallowed whole and not crushed or chewed unless the prescribing information specifically allows a liquid formulation.

Serious adverse events include hepatotoxicity (liver injury), congestive heart failure due to fluid retention, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and visual disturbances. Patients should report any signs of liver dysfunction, shortness of breath, swelling, or rash promptly.

Itraconazol Cinfa is contraindicated in individuals with known hypersensitivity to itraconazole or any azole antifungal, patients with established congestive heart failure, and those with severe hepatic impairment. Caution is also advised for patients taking strong CYP3A4 inducers or drugs that may cause additive toxicity.